coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Sasse Network 1 PCN, Spelthorne · Health Inequalities Profile

    PCN U46901 · NHS Surrey Heartlands Integrated Care Board; NHS Surrey and Sussex Integrated Care Board · 4 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    52,022

    Registered population

    58.8% aged 18–64

    21.4%

    Aged 65+

    ICB 18.8% · England 17.9%

    20.9%

    Ethnic minority (non-White)

    12.4% Asian · England 9.6%

    0.0%

    In IMD quintile 1

    ICB 0.8% · England 21.0%

    0

    Core20 residents (est.)

    Resident basis; registered basis 0 · see page 3

    8,958

    Hypertension register

    +4.11% in 3 yrs · England +5.60%

    420

    SMI register

    47.2% of Spelthorne's

    854

    COPD register

    Reviews +5.67% in 3 yrs

    Forecast to 2030

    10,270

    Hypertension patients, 2030

    +1,312 on today

    69.6%

    QRISK ≥20% on statins, 2030

    +4.35pp over 3 yrs

    5.9%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    7 pp
    Pre-school booster coverage drops at age five.

    Age-5 MMR coverage drops 7 pp from 96.2% (dose 1) to 89.2% (dose 2), with 4-in-1 at 87.7%, below the 95.0% target.

    59.9%
    Lipid therapy lags alongside higher unit costs.

    QRISK >= 20% lipid therapy is 59.9% (England 63.6%), while lipid-modifying items cost £2.70 (£60,620 more than at England's £1.86 unit cost).

    72.4%
    Hypertension blood pressure control exceeds comparator benchmarks.

    Among hypertension patients, 90.2% have a recent blood pressure reading and 72.4% are treated to target, above Spelthorne (69.5%) and England (70.3%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Older age profile and concentrated borough inclusion health caseloads shape local primary care

    Across 52,022 registered patients, 21.4% (11,154 patients) are aged 65+, above Spelthorne (17.4%), the ICB (18.8%) and England (17.9%). Working-age adults (18-64) comprise 58.8% and children (0-17) 19.8%. Projected list growth to 2030 is 5.6%, matching Spelthorne (5.6%) and above the ICB (4.9%) and England (2.3%), though projection methodology is unverified. In associated areas, 20.9% of usual residents are from ethnic minorities, with 12.4% Asian or Asian British (Spelthorne 12.8%, ICB 7.7%, England 9.6%) and 79.1% White. Census resident ethnicity does not reflect registered-patient ethnicity.

    Age profile

    0–1719.8%
    18–6458.8%
    65+21.4%

    65+: ICB 18.8%, England 17.9%

    Ethnicity

    White79.1%
    Asian12.4%
    Mixed3.7%
    Black2.5%
    Other2.3%

    Older people · falls rows are Spelthorne local-authority (LA) data, not PCN

    MeasureLocalSouth EastEnglandPeriod
    Falls admissions, 65+, per 100,000 (Spelthorne LA)1,8752,0181,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)80.1%82.2%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)58.1%57.8%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Spelthorne LA)9509819552024/25
    Falls deaths, all ages, per 100,000 (Spelthorne LA)10.714.014.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 registered population is 0.0% PCN-wide, alongside an average IMD decile of 6.9

    The PCN average IMD decile is 6.9, above Spelthorne (6.5) and England (5.5), and below NHS Surrey Heartlands Integrated Care Board (7.9). The registered Core20 cohort is 0.0%, below Spelthorne (1.8%), NHS Surrey Heartlands Integrated Care Board (0.8%), and England (21.0%). Practice Core20 rates reconcile at 0.0% across all four practices (0 estimated Core20 patients), with average IMD deciles spanning from 6.1 at Studholme Medical Centre to 7.4 at Shepperton Medical Practice. With zero Core20 residents, area deprivation metrics do not capture local health inequalities, requiring individual clinical risk identification.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Sunbury0.0% · 0 patients
    Shepperton0.0% · 0 patients
    Studholme0.0% · 0 patients
    Upper Halliford0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    420

    SMI register

    0.81% recorded prevalence

    186

    Learning disability register

    0.36% recorded prevalence

    12

    Care homes, 557 beds

    In the PCN catchment

    8.6%

    Provide unpaid care

    Spelthorne, Census 2021

    The PCN records 420 patients on its severe mental illness register and 186 on its learning disability register, comprising 47.2% and 48.3% of Spelthorne's borough totals. Catchment sites include 12 care homes with 557 beds. Concentrated borough inclusion health registers indicate substantial tailored physical health check and care home coordination needs across the network.

    Severe mental illness: physical health checks

    On the 420-patient severe mental illness register, BMI recording is 86.9% (England 82.1%), while 3-year blood pressure check growth of +2.7 pp trails England (+4.4 pp) and alcohol recording is 79.2% (England 81.8%).

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    8,958

    Hypertension register

    +4.11%

    Register growth, 3 yrs

    Spelthorne +4.33% · England +5.60%

    +3.62pp

    BP control, under 80

    ≤140/90 · +1.70pp aged 80+

    +1,312

    More patients by 2030

    Forecast 10,270 (18.65%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 17.2% (8,958 patients), above Spelthorne (15.7%), NHS Surrey Heartlands Integrated Care Board (14.3%) and England (15.2%). Among registered patients, 90.2% have a recent blood pressure reading (England 90.0%) and 72.4% are treated to target (England 70.3%). Three-year register growth of +4.1% trails England (+5.6%) and the ICB (+5.3%). Practice prevalence spans from 15.2% at Upper Halliford Medical Centre to 19.6% at Shepperton Medical Practice. Crude prevalence differences do not establish undiagnosed disease, and the unverified 2030 projection of 10,270 patients is for planning scale only.

    Lipids and statins

    At 59.9%, lipid-lowering therapy for patients with QRISK ≥ 20% trails Spelthorne (61.7%) and England (63.6%), though it exceeds NHS Surrey Heartlands Integrated Care Board (59.4%). Statin treatment in diabetes with cardiovascular disease is 82.8% (England 84.4%).

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202672,167£2.70£2.24£1.86£194,851
    Cardiovascular (all), 2025102,902£5.45£4.74£3.33£560,816

    In 2026, the PCN prescribed 72,167 lipid-modifying items at £2.70 per item, above Spelthorne (£2.36), NHS Surrey Heartlands Integrated Care Board (£2.24) and England (£1.86). This unit cost is £60,620 more than at England's unit cost, across 72,167 items.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +1.06%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +4.54%

    Asthma prevalence, PCN 3-yr % change

    Across 854 registered patients, COPD annual reviews reach 82.9% (England 76.4%, Spelthorne 85.9%) with 3-year growth of +5.7% (England +2.8%). Asthma reviews reach 68.0% across 2,912 registered patients (Spelthorne 70.6%), with 3-year growth of +1.1% (England +4.4%), leaving about 930 patients (931) unreviewed. Asthma management items prescribed per 1000 5-19 Population is 917 rate (England 1,488 rate).

    Cancer register and children's immunisation

    The cancer register records 2,588 patients (5.0%, England 3.8%). At age 5, MMR dose 1 coverage is 96.2%, exceeding the 95.0% target. MMR dose 2 coverage is 89.2%, trailing dose 1 by 7 pp and falling 5.8 pp below the 95.0% target. Coverage for the 4-in-1 pre-school booster is 87.7%, 7.3 pp below the 95.0% target.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months91.5%

    England 91.0%

    6-in-1 complete primary course at 24 months91.9%

    England 92.2%

    MMR dose 1 at 24 months89.2%

    England 88.3%

    MMR dose 2 at age 589.2%

    England 82.8%

    4-in-1 pre-school booster at age 587.7%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    61.4%

    Surrey Heartlands ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~650

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Surrey Heartlands ICBEnglandNo usable stageStaged cancers
    Prostate65.7%53.2%18%1,044
    Breast88.2%85.4%27%798
    Bowel48.1%47.0%18%626
    Lung33.2%33.8%17%497
    Skin cancer89.8%87.8%19%384

    Across NHS Surrey Heartlands ICB in 2022, 61.4% of cancers with a known stage (2,955 of 4,810) were diagnosed at stage 1 or 2, above England (55.3%) but 13.6 percentage points below the 75.0% national ambition (about 650 additional cases needed; tumour cohorts vary). Known-stage coverage was 67.7% (4,810 of 7,106 registered cancers), describing wider system staging rather than PCN performance. Locally, cervical screening aged 25-49 is 70.8% (England 66.8%) but fell 2.8% over three years (England -1.0%), trailing at Upper Halliford Medical Centre (65.8%).

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    At Ashford and St Peter's Hospitals NHS Foundation Trust in July 2026 (provisional), the 62-day referral to treatment standard reached 76.4%, above England (71.2%) and NHS Surrey and Sussex Integrated Care Board (71.5%), but 8.6 percentage points below the 85.0% standard. The 28-day faster diagnosis standard achieved 85.5% (England 79.3%). Diagnostic delays remain concentrated in endoscopy, with 49.6% waiting 6+ weeks for colonoscopy and 57.9% for flexi sigmoidoscopy (England 30.8% and 32.1%), whereas MRI waits of 6+ weeks were 0.1% (England 21.4%). These provider-level figures describe system diagnostic waits rather than PCN pathway management.

    Pathways within standard (%)Ashford and St Peter'sChelsea and WestminsterKingston and RichmondSurrey and Sussex ICBEngland
    28-day faster diagnosis (75%)85.5383.2280.0779.2979.32
    31-day treatment (96%)94.2197.6098.7790.4592.50
    62-day referral to treatment (85%)76.3890.4175.3271.5171.16
    Diagnostic waits over 6 weeks (%)Ashford and St Peter'sChelsea and WestminsterKingston and RichmondEngland
    MRI0.098.150.1921.40
    CT9.2724.360.009.92
    Echocardiography0.9722.934.8928.48
    Colonoscopy49.617.0470.1730.83
    Gastroscopy56.742.2079.1829.02
    All 15 DM01 tests23.1218.6131.5623.14
    Community services activitySurrey residentsSurrey and Sussex ICB
    Care contacts109,530309,615
    Referrals28,70066,930
    Patients with a contact33,51085,660

    Community services (residents of Surrey), Jun 2026 (provisional). In the Community Services Dataset for June 2026 (provisional), 69.6% of community contacts with Spelthorne residents (76,215 of 109,530) were for adults aged 65+. These borough-level figures reflect wider system engagement among older cohorts rather than PCN-specific intermediate care delivery.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Patient phone access spans 19.5 percentage points across the PCN's four practices

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Shepperton1220.045.1%71.9%85.2%
    Sunbury1090.055.9%78.1%75.6%
    Upper Halliford1310.039.6%61.8%68.3%
    Studholme910.036.4%76.6%63.5%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNSpelthorneAssetPCNSpelthorne
    Care homes (catchment)12 (557 beds)n/aSchools (catchment)53n/a
    Children's centres56Places of worship2843
    Libraries11Homelessness support (VCS)0no data
    Day centres (VCS)n/a1Carers support groups (VCS)n/a1
    Primary schools (LA maintained)88Primary academies68

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Pre-school booster and MMR2 catch-up

    At age 5 (130 children), MMR1 is 96.2% while MMR2 is 89.2% (7 pp lower; 5.8 pp below the 95.0% target) and 4-in-1 is 87.7% (7.3 pp below target). For discussion: practices could audit age-5 cohorts for overdue MMR2 and 4-in-1 doses and test flexible catch-up clinics. Low cost, quick to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Option 2

    Structured asthma annual review recall

    Asthma review coverage is 68.0% of the 2,912 register, below Spelthorne (70.6%) with +1.1% 3-year change (England +4.4%), leaving 931 (about 930) unreviewed. For discussion: the PCN could run a single asthma recall template and offer after-school or flexible review slots alongside inhaler checks. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 3

    Lipid therapy and formulary review

    QRISK ≥ 20% lipid therapy is 59.9% (England 63.6%). Across 72,167 lipid-modifying items, unit cost (£2.70 vs £1.86 England) is £60,620 more than England's unit cost. For discussion: clinical pharmacists could audit high-QRISK patients not on lipid-lowering therapy and review lipid-modifying formulary choices. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Clinical inclusion health register audit (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical health recall audit (p4)Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Hypertension case-finding audit (p5)Hypertension: QOF prevalenceCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall catch-up (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Telephony and access review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Pre-school booster and MMR2 catch-up (p12)MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Option 2 · Structured asthma annual review recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 3 · Lipid therapy and formulary review (p12)Patients with QRISK ≥ 20% treated with lipid lowering therapy · Cost per item for Lipid-regulating drugs 2026 · Count of Items prescribed for Lipid-regulating drugs 2026Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026ICB2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15